In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aquestive Therapeutics (AQST), with a price target of $32.00. The company’s shares closed last Thursday at $7.33.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.3% and a 50.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
Aquestive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.00, representing a 130.8% upside. In a report issued on November 5, RBC Capital also maintained a Buy rating on the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
Based on Aquestive Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $8.26 million and GAAP net loss of $16.55 million. In comparison, last year the company earned revenue of $12.42 million and had a GAAP net loss of $18.41 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
Read More on AQST:
